Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Organization

BioXcel Therapeutics

12 clinical trials

1 abstract

Clinical trial
Characterization of Tachyphylaxis, Tolerance, and Withdrawal After Discontinuation of Igalmi in Frequently Agitated Schizophrenic or Bipolar Patients After 7 Days of PRN Treatment
Status: Recruiting, Estimated PCD: 2024-04-01
Clinical trial
A Phase 1b/2 Randomized, Double-Blind, Placebo-Controlled, Ascending-Dose Study of BXCL501 to Treat Symptoms of Acute Opioid Withdrawal in Patients With Opioid Use Disorder Who Are Physically Dependent on Opioids
Status: Completed, Estimated PCD: 2021-02-18
Clinical trial
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy, and Safety Study of BXCL501 For The Treatment of Agitation Associated With Dementia
Status: Terminated, Estimated PCD: 2022-04-01
Clinical trial
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy And Safety Study of PRN Dosing of BXCL501 Over A 12 Week Period In Subjects With Agitation Associated With Dementia
Status: Completed, Estimated PCD: 2023-04-21
Clinical trial
A Phase III Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine Efficacy and Safety of BXCL501 In Agitation Associated With Bipolar Disorder
Status: Completed, Estimated PCD: 2020-05-21
Clinical trial
Phase 1b/2 Study of BXCL701, a Small Molecule Inhibitor of Dipeptidyl Peptidases, Administered in Combination With the Anti-Programmed Cell Death 1 Monoclonal Antibody Pembrolizumab in Patients With mCRPC Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma Phenotype
Status: Active (not recruiting), Estimated PCD: 2023-10-01
Clinical trial
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of PRN Dosing of BXCL501 Over a 12 Week Treatment Period in Subjects With Agitation Associated With Dementia
Status: Terminated, Estimated PCD: 2023-09-11
Clinical trial
Efficacy And Safety of BXCL501 Evaluated For At-Home Use In A Multisite Double-Blind Placebo-Controlled Trial For Agitation Associated With Schizophrenia And Bipolar Disorder
Status: Active (not recruiting), Estimated PCD: 2025-03-30
Clinical trial
A Phase III Multicenter, Randomized, Double-Blind, Placebo-Controlled Study To Determine Efficacy and Safety of BXCL501 In Agitation Associated With Schizophrenia
Status: Completed, Estimated PCD: 2020-05-06
Clinical trial
A Randomized, Double-blind, Placebo-controlled Study to Determine Efficacy and Safety of BXCL501 in Agitation Associated With Pediatric Schizophrenia and Bipolar Disorder
Status: Recruiting, Estimated PCD: 2024-07-31
Clinical trial
A Phase Ib Multicenter, Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Study to Determine Efficacy, Pharmacokinetics and Safety of BXCL501 in Agitation Associated With Schizophrenia
Status: Completed, Estimated PCD: 2019-07-31
Clinical trial
A Phase Ib/II, Multicenter, Randomized, Double Blind, Placebo Controlled, Ascending Dose Finding, Efficacy, Pharmacokinetic and Safety Study of BXCL501 In Agitation Associated With Dementia
Status: Completed, Estimated PCD: 2022-01-24
Abstract
First-in-class oral innate immune activator BXCL701 combined with pembrolizumab, in patients with metastatic castration-resistant prostate cancer (mCRPC) of small cell neuroendocrine (SCNC) variant: Randomized phase 2b trial.
Org: Moffitt Cancer Center, The Ohio State University Comprehensive Cancer Center – James Cancer Hospital & Solove Research Institute, Northwell Health, New Hyde Park, NY, Center for Cancer Care at White Plains Hospital, Yale School of Medicine,